Tenaya Therapeutics, Inc. (TNYA): restructuring charge — Tenaya Therapeutics approves restructuring; workforce reduction extends cash runway to H2 2026

Tenaya Therapeutics, Inc.

Restructuring focuses resources on TN-201 (MyPEAK-1) and TN-401 (RIDGE-1) gene therapy trials.
Workforce reduction implemented; no expected impact on enrollment milestones or data readouts.
Estimated severance and health benefit charges of $1.6M–$2.7M, substantially all by Q3 2025.
Cash runway extended into second half of 2026 via cost-containment measures.
Sufficient drug product produced for ongoing trials; manufacturing for pivotal studies continues.

item 2.05

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Tenaya Therapeutics, Inc. announced a restructuring with charges of approximately $1.6 million to $2.7 million.

Type: restructuring
Charge: approximately $1.6 million to $2.7 million

Exact text from the filing

as planned. Key capabilities to support early research have also been retained. In connection with the Restructuring Plan, Tenaya estimates that it will incur approximately $1.6 million to $2.7 million of aggregate charges, primarily related to employee cash severance and continuing health benefits. Tenaya expects to recognize substantially all of the charges by

View on SEC.gov

Browse all restructurings & charges →

Tenaya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-067071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.